FY2025 Earnings Forecast for CMPS Issued By Lifesci Capital

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Lifesci Capital issued their FY2025 earnings estimates for COMPASS Pathways in a report issued on Thursday, February 12th. Lifesci Capital analyst F. Brisebois anticipates that the company will post earnings per share of ($1.66) for the year. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share. Lifesci Capital also issued estimates for COMPASS Pathways’ Q4 2025 earnings at ($0.47) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($1.84) EPS.

A number of other analysts also recently commented on CMPS. Compass Point set a $15.00 price target on COMPASS Pathways in a research report on Thursday. Morgan Stanley raised their price objective on shares of COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Royal Bank Of Canada lifted their price objective on shares of COMPASS Pathways from $16.00 to $21.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.11.

COMPASS Pathways Trading Down 0.7%

NASDAQ:CMPS opened at $5.81 on Monday. COMPASS Pathways has a 52 week low of $2.25 and a 52 week high of $8.20. The firm has a 50-day moving average price of $6.74 and a two-hundred day moving average price of $5.87. The firm has a market cap of $557.88 million, a price-to-earnings ratio of -2.14 and a beta of 1.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23.

Hedge Funds Weigh In On COMPASS Pathways

Several hedge funds have recently bought and sold shares of the company. Advisory Services Network LLC purchased a new stake in COMPASS Pathways in the 3rd quarter worth approximately $41,000. BIT Capital GmbH bought a new position in shares of COMPASS Pathways in the third quarter worth $54,000. MML Investors Services LLC purchased a new stake in shares of COMPASS Pathways in the fourth quarter worth $69,000. Raymond James Financial Inc. boosted its stake in COMPASS Pathways by 82.7% during the third quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock valued at $79,000 after buying an additional 6,228 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of COMPASS Pathways during the 4th quarter valued at about $96,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.